“It’s time to reevaluate 340B intermediary relationships and ask who they serve”

Citing compliance concerns, specifically duplicate discounts, several drug manufacturers took steps to reduce contract pharmacy access to 340B-priced drugs. The move has caused an outcry from covered entities, many of which depend on contract pharmacies to expand patient access, particularly in rural areas.